IBDEI14P ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19203,0)
 ;;=90472^^83^911^2^^^^1
 ;;^UTILITY(U,$J,358.3,19203,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,19203,1,2,0)
 ;;=2^90472
 ;;^UTILITY(U,$J,358.3,19203,1,3,0)
 ;;=3^Immunization Admin,Ea Addl
 ;;^UTILITY(U,$J,358.3,19204,0)
 ;;=90658^^83^912^3^^^^1
 ;;^UTILITY(U,$J,358.3,19204,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,19204,1,2,0)
 ;;=2^90658
 ;;^UTILITY(U,$J,358.3,19204,1,3,0)
 ;;=3^Flu Vaccine IM (Flulaval)
 ;;^UTILITY(U,$J,358.3,19205,0)
 ;;=90658^^83^912^4^^^^1
 ;;^UTILITY(U,$J,358.3,19205,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,19205,1,2,0)
 ;;=2^90658
 ;;^UTILITY(U,$J,358.3,19205,1,3,0)
 ;;=3^Flu Vaccine Single Dose Syringe (Afluria)
 ;;^UTILITY(U,$J,358.3,19206,0)
 ;;=90662^^83^912^2^^^^1
 ;;^UTILITY(U,$J,358.3,19206,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,19206,1,2,0)
 ;;=2^90662
 ;;^UTILITY(U,$J,358.3,19206,1,3,0)
 ;;=3^Flu Vaccine High Dose Syringe (Fluzone)
 ;;^UTILITY(U,$J,358.3,19207,0)
 ;;=90715^^83^912^6^^^^1
 ;;^UTILITY(U,$J,358.3,19207,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,19207,1,2,0)
 ;;=2^90715
 ;;^UTILITY(U,$J,358.3,19207,1,3,0)
 ;;=3^TdaP Vaccine IM
 ;;^UTILITY(U,$J,358.3,19208,0)
 ;;=90732^^83^912^5^^^^1
 ;;^UTILITY(U,$J,358.3,19208,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,19208,1,2,0)
 ;;=2^90732
 ;;^UTILITY(U,$J,358.3,19208,1,3,0)
 ;;=3^Pneumococcal Vaccine
 ;;^UTILITY(U,$J,358.3,19209,0)
 ;;=90736^^83^912^7^^^^1
 ;;^UTILITY(U,$J,358.3,19209,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,19209,1,2,0)
 ;;=2^90736
 ;;^UTILITY(U,$J,358.3,19209,1,3,0)
 ;;=3^Zoster (Shingles) Vaccine
 ;;^UTILITY(U,$J,358.3,19210,0)
 ;;=90697^^83^912^1^^^^1
 ;;^UTILITY(U,$J,358.3,19210,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,19210,1,2,0)
 ;;=2^90697
 ;;^UTILITY(U,$J,358.3,19210,1,3,0)
 ;;=3^DTAP-IPV-Hib-HepB IM
 ;;^UTILITY(U,$J,358.3,19211,0)
 ;;=B18.2^^84^913^26
 ;;^UTILITY(U,$J,358.3,19211,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19211,1,3,0)
 ;;=3^Hepatitis C,Chr
 ;;^UTILITY(U,$J,358.3,19211,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,19211,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,19212,0)
 ;;=C44.99^^84^913^50
 ;;^UTILITY(U,$J,358.3,19212,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19212,1,3,0)
 ;;=3^Skin Cancer,Unspec
 ;;^UTILITY(U,$J,358.3,19212,1,4,0)
 ;;=4^C44.99
 ;;^UTILITY(U,$J,358.3,19212,2)
 ;;=^5001094
 ;;^UTILITY(U,$J,358.3,19213,0)
 ;;=E11.9^^84^913^15
 ;;^UTILITY(U,$J,358.3,19213,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19213,1,3,0)
 ;;=3^Diabetes Type 2
 ;;^UTILITY(U,$J,358.3,19213,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,19213,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,19214,0)
 ;;=E11.40^^84^913^16
 ;;^UTILITY(U,$J,358.3,19214,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19214,1,3,0)
 ;;=3^Diabetes Type 2 w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,19214,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,19214,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,19215,0)
 ;;=E78.2^^84^913^27
 ;;^UTILITY(U,$J,358.3,19215,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19215,1,3,0)
 ;;=3^Hyperlipidemia,Mixed
 ;;^UTILITY(U,$J,358.3,19215,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,19215,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,19216,0)
 ;;=E78.5^^84^913^28
 ;;^UTILITY(U,$J,358.3,19216,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19216,1,3,0)
 ;;=3^Hyperlipidemia,Unspec
 ;;^UTILITY(U,$J,358.3,19216,1,4,0)
 ;;=4^E78.5
 ;;^UTILITY(U,$J,358.3,19216,2)
 ;;=^5002969
 ;;^UTILITY(U,$J,358.3,19217,0)
 ;;=E66.3^^84^913^44
 ;;^UTILITY(U,$J,358.3,19217,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19217,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,19217,1,4,0)
 ;;=4^E66.3
